 |
TTP had
a significant involvement in the development of
the Dex blood glucose system for Bayer, from generating
fundamental instrument patents to developing and
supplying key elements of the QA system. |
| |
|
 |
TTP's TouchSpray®
technology has been licensed to PARI GmbH.
This technology, in the form of the eFlow
electronic nebuliser, delivers medication very
efficiently to the
lungs. |
| |
|
 |
TTP’s proprietary microchemistry
platform allows complex applications of laboratory
biochemistry to be undertaken on a low cost disposable
card. It has applications for example in healthcare
diagnostics and screening and can also be used for
environmental and process monitoring. |
|
|
 |
IVAX UK's Airmax™ multi-dose
dry powder inhaler is currently being licensed by
Novartis for European markets. Airmax™ was
developed from a very early conceptual stage
through to manufacture and clinical trials. |
